Mylan Specialty L.P.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$21.3M
Doctors Paid
43,129
Transactions
180,892
2024 Total
$2.9M
Payment Breakdown by Category
Research$10.8M (50.5%)
Food & Beverage$3.5M (16.4%)
Consulting$1.4M (6.4%)
Travel$709,985 (3.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.8M | 982 | 50.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.6M | 3,482 | 21.6% |
| Food and Beverage | $3.5M | 172,044 | 16.4% |
| Consulting Fee | $1.4M | 1,055 | 6.4% |
| Travel and Lodging | $709,985 | 3,024 | 3.3% |
| Grant | $193,605 | 10 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $72,199 | 48 | 0.3% |
| Education | $70,685 | 244 | 0.3% |
| Charitable Contribution | $29,100 | 3 | 0.1% |
Payments by Type
Research
$10.8M
982 transactions
General
$10.6M
179,910 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | $5.9M | 0 | 696 |
| A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | $938,268 | 0 | 94 |
| SB16A1.07 | $758,760 | 0 | 12 |
| Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO) | $382,779 | 0 | 17 |
| XULA-TD-1004 | $350,011 | 0 | 4 |
| Prevalence of Impairments in Cognitive Function and Manual Dexterity in Out-patients with COPD and Associations with Correct Inhaler Techniques | $335,900 | 0 | 5 |
| DOM-19001 | $285,000 | 1 | 8 |
| Emergency Department Management of Patients with Food or Insect Sting Allergies: 38th Multicenter Airway Research Collaboration (MARC-38) Study | $252,555 | 0 | 1 |
| XULA-TD-1005 | $205,605 | 0 | 5 |
| TWRL-TD-1001 | $165,501 | 0 | 6 |
| ROTI-TD-1005 | $154,478 | 0 | 5 |
| Research_A Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin administered before Nebulized Formoterol Fumarate (PER | $122,083 | 1 | 15 |
| Differentiating the Effects of Long-acting Bronchodilators Administered by Nebulizer versus Dry Powder Inhaler in Symptomatic Patients with Chronic Obstructive Pulmonary Disease | $109,886 | 0 | 9 |
| Development of an Electronic Registry to Determine Prevalence and Characteristics of Anaphylaxis and Epinephrine Use | $80,614 | 0 | 1 |
| Research_Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate Safety and Tolerability of Nebulized Revefenacin administered before Nebulized Formoterol Fumarate | $80,032 | 1 | 23 |
| Subramaniam-The Effect of Intraoperative Continuous Remifentanil Infusion on Glycemic Response and Variability | $69,375 | 0 | 1 |
| PIFR 2 | $52,500 | 0 | 37 |
| A qualitative study to understand patient & social factors related to nebulizer use at the transition of care in COPD | $51,576 | 0 | 4 |
| CTBM100CUS03T | $50,586 | 0 | 1 |
| Improving Food Allergy Verification and EpiPen Auto-Injector Access in the Chicago Public Schools | $50,000 | 0 | 1 |
| The Effect of Intraoperative Continuous Remifentanil Infusion on Glycemic Response and Variability | $41,625 | 0 | 2 |
| Long-acting Bronchodilators Administered by Nebulizer vs Dry Powder Inhaler in Symptomatic Patients with Chronic Obstructive Pulmonary Disease | $41,572 | 0 | 2 |
| Nebulized LAMA Program in a Healthcare System | $40,000 | 0 | 1 |
| Elucidating the Epidemiology of Anaphylaxis in the Elderly | $37,396 | 0 | 2 |
| Understanding Anaphalaxis in Camps: A study measuring demographics, knowledge, and incidence of allergic reactions | $33,982 | 0 | 1 |
| Elucidating the Epidemiology of Anaphylaxis in the Eldery | $30,596 | 0 | 2 |
| National Registry of Food Allergy Treatment | $30,000 | 0 | 2 |
| PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO | $29,542 | 0 | 4 |
| Identifying Clinically Relevant PIF Cutoffs | $28,800 | 0 | 1 |
| Understanding Patients Practices for Keeping Multiple Epinephrine Auto-injectors in Multiple Locations | $25,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Mark Pamer, D.o, D.O | Critical Care Medicine | Port Saint Lucie, FL | $186,695 | $0 |
| Antonio Anzueto, Md, MD | Pulmonary Disease | San Antonio, TX | $180,892 | $0 |
| Prof. Rajiv Dhand, Md, MD | Pulmonary Disease | Knoxville, TN | $152,323 | $0 |
| Dr. William Alleyne, M.d, M.D | Critical Care Medicine | Rock Hill, SC | $110,037 | $0 |
| Aaron Milstone, Md, MD | Pulmonary Disease | Franklin, TN | $96,613 | $0 |
| Dr. William Mckenzie, M.d, M.D | Specialist | Panama City, FL | $95,297 | $0 |
| Dr. Tarun Madappa, M.d, M.D | Internal Medicine | Corpus Christi, TX | $92,675 | $0 |
| Mr. Asaad Jandali, M.d, M.D | Sleep Medicine | Munster, IN | $92,114 | $0 |
| Dr. Fariborz Rezai, M.d, M.D | Internal Medicine | Livingston, NJ | $88,975 | $0 |
| Israel Rubinstein | Critical Care Medicine | Chicago, IL | $82,035 | $0 |
| Dr. Ryan Reber, D.o, D.O | Internal Medicine | Wynnewood, PA | $78,641 | $0 |
| Abhijit Raval, Md, MD | Internal Medicine | Anderson, SC | $78,521 | $0 |
| Alfred Habel, Md, MD | Internal Medicine | Kenosha, WI | $78,208 | $0 |
| Dr. Jeffrey Wolf, M.d, M.D | Pulmonary Disease | Great Neck, NY | $76,625 | $0 |
| Gary Ferguson, M.d, M.D | Internal Medicine | Livonia, MI | $74,292 | $0 |
| David Mares, Md, MD | Critical Care Medicine | Anderson, IN | $74,097 | $0 |
| Dr. James Donohue, Md, MD | Pulmonary Disease | Chapel Hill, NC | $73,010 | $0 |
| Mohammad Sheatt, Md, MD | Critical Care Medicine | Cincinnati, OH | $71,164 | $0 |
| Dr. George Parides, Do, DO | Pulmonary Disease | Mesa, AZ | $71,072 | $0 |
| Michael Pietila, M.d, M.D | Pulmonary Disease | Yankton, SD | $68,163 | $0 |
| Dr. Michael Wert, M.d, M.D | Internal Medicine | Greensboro, NC | $65,585 | $0 |
| Muhammad Afzal, M.d, M.D | Pulmonary Disease | Sacramento, CA | $63,405 | $0 |
| Donald Tashkin, Md, MD | Pulmonary Disease | Los Angeles, CA | $61,276 | $0 |
| Dr. Nashat Rabadi, Md, MD | Critical Care Medicine | Buffalo, NY | $59,349 | $0 |
| Dr. Donald Mahler, M.d, M.D | Pulmonary Disease | Lebanon, NH | $58,719 | $0 |
Ad
Top Products
- Yupelri $9.2M
- YUPELRI $7.6M
Associated Products (9)
- Yupelri $9.3M
- YUPELRI $7.6M
- Dymista $1.1M
- EpiPen $504,345
- Ultiva $189,341
- Perforomist $148,869
- TOBI Podhaler $119,146
- Tobi Podhaler $24,700
- GLATIRAMER ACETATE $12,536
Payment Categories
- Food & Beverage $3.5M
- Consulting $1.4M
- Travel & Lodging $709,985
- Research $10.8M
About Mylan Specialty L.P.
Mylan Specialty L.P. has made $21.3M in payments to 43,129 healthcare providers, recorded across 180,892 transactions in the CMS Open Payments database. In 2024, the company paid $2.9M. The top product by payment volume is Yupelri ($9.2M).
Payments were distributed across 231 medical specialties. The top specialty by payment amount is Pulmonary Disease ($3.0M to 2,872 doctors).
Payment categories include: Food & Beverage ($3.5M), Consulting ($1.4M), Research ($10.8M), Travel & Lodging ($709,985).
Mylan Specialty L.P. is associated with 9 products in the CMS Open Payments database, including Yupelri, YUPELRI, and Dymista.